Genfit S.A. (EPA:GNFT)
France · Delayed Price · Currency is EUR | Market Cap | 443.18M +120.5% |
| Revenue (ttm) | 65.43M -7.4% |
| Net Income | -85.97M |
| EPS | -1.72 |
| Shares Out | 49.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 157,820 |
| Average Volume | 205,104 |
| Open | 8.90 |
| Previous Close | 8.90 |
| Day's Range | 8.73 - 9.02 |
| 52-Week Range | 3.05 - 9.72 |
| Beta | 1.08 |
| RSI | 58.12 |
| Earnings Date | Sep 29, 2026 |
About Genfit
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien... [Read more]
Financial Performance
Financial StatementsNews
GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 11, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with ra...
GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 20, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with ...
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
Lille, France; Cambridge, MA; Zurich, Switzerland; April 2, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threa...
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 9, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with r...
GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 12, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients wi...
GENFIT Announces 2026 Financial Calendar
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of pa...
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 10, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients wi...
GENFIT Announces Appointment of new Chief Medical Officer
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 27, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients wi...
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
GENFIT announces the Company's voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Global Selec
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...
Genfit announces intention to voluntarily delist ADSs from Nasdaq
Genfit (GNFT) announced it has given formal notice to the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares. The delisting is anticipated to be effective…
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market
Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); October 30, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...
GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), October 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of p...
Genfit price target lowered to $7 from $9 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Genfit (GNFT) to $7 from $9 and keeps a Buy rating on the shares. The company last week announced the discontinuation of…
GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update
Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); September 22, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving ...
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of...
Genfit assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of Genfit (GNFT) with a Buy rating and $9 price target The company is developing therapies for rare and severe liver diseases, with a focus on…
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patie...
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of pati...
GENFIT Reports First Quarter 2025 Financial Information
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the liv...
Genfit to receive EUR 26.5M Iqirvo milestone payment from Ipsen agreement
Genfit (GNFT) announced that Ipsen’s Iqirvo has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis. This step unlocks a new milestone payment of EUR 26.5M under its…
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of pati...
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patien...